Cargando…

Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome

Rationale: An effective absorbed dose response relationship is yet to be established for Lutetium-177 based radionuclide therapies such as (177)Lu-DOTATATE and (177)Lu-PSMA. The inherent biological heterogeneity of neuroendocrine and prostate cancers may make the prospect of establishing cohort-base...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Neill, Edward, Mosley, Michael, Cornelissen, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008745/ https://www.ncbi.nlm.nih.gov/pubmed/36923536 http://dx.doi.org/10.7150/thno.82101

Ejemplares similares

Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
por: Saracyn, Marek, et al.
Publicado: (2022)

Safety and Efficacy of (177)Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing (223)Radium-Dichloride
por: Baumgarten, Justus, et al.
Publicado: (2022)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
por: Ritawidya, Rien, et al.
Publicado: (2023)

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen
por: Rathore, Rajni, et al.
Publicado: (2023)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
por: Gallyamov, Marat, et al.
Publicado: (2019)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Adoption of Lutetium-(177) PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020
por: Flegar, Luka, et al.
Publicado: (2023)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review
por: Sutherland, Duncan E. K., et al.
Publicado: (2023)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy
por: Cappon, Derek John, et al.
Publicado: (2023)

SHDB mutant functional metastatic paraganglioma: The efficacy of Lutetium-177 DOTATE
por: Erturk, Banu, et al.
Publicado: (2023)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
por: Kesavan, Murali, et al.
Publicado: (2021)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Metastatic MEN1 Syndrome Treated with Lutetium-177 – A Case Report
por: Gezer, Emre, et al.
Publicado: (2019)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
por: Werner, Rudolf A., et al.
Publicado: (2014)

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
por: Digklia, Antonia, et al.
Publicado: (2022)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2022)

Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems
por: Peters, Steffie M. B., et al.
Publicado: (2020)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
por: Assadi, Majid, et al.
Publicado: (2020)

Genome-wide multi-parametric analysis of H2AX or γH2AX distributions during ionizing radiation-induced DNA damage response
por: Natale, Francesco, et al.
Publicado: (2013)

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
por: Hosono, Makoto, et al.
Publicado: (2018)

The HINT1 tumor suppressor regulates both γ-H2AX and ATM in response to DNA damage
por: Li, Haiyang, et al.
Publicado: (2008)

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
por: Mendez, Lucas C., et al.
Publicado: (2023)

Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model
por: Lindenblatt, Dennis, et al.
Publicado: (2014)

Software-assisted dosimetry in peptide receptor radionuclide therapy with (177)Lutetium-DOTATATE for various imaging scenarios
por: Kupitz, Dennis, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s46rug970d49314f7i14vtr5i3